Glenmede Trust’s Ascendis Pharma A/S ASND Stock Holding History

Glenmede Trust’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,990	Closed	-$294K	–	2457
2020 Q2	$294K	Buy	1,990 +505	+34%	+$69.3K	﹤0.01%	913
2020 Q1	$206K	Hold	1,485	–	–	﹤0.01%	1187
2019 Q4	$206K	Buy	+1,485	New	+$165K	﹤0.01%	1187

Other funds holding ASND

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Glenmede Trust's ASND Position: Q3 2020 in Review

Glenmede Trust sold out of Ascendis Pharma A/S (ASND) in Q3 2020, closing a stake of 1,990 shares — an estimated $294K sold.

Glenmede Trust first reported a position in ASND in Q4 2019 and held it in 3 quarters. The position peaked at $294K in Q2 2020. 152 funds tracked by Wall St. Rank hold ASND as of Q3 2020.

Glenmede Trust reported no remaining Ascendis Pharma A/S position as of Q3 2020 after selling out during the quarter.
Glenmede Trust sold 1,990 Ascendis Pharma A/S shares in Q3 2020, an estimated $294K.
Glenmede Trust first reported a position in Ascendis Pharma A/S in Q4 2019 and held it in 3 quarters.
Glenmede Trust's Ascendis Pharma A/S position peaked at $294K in Q2 2020.
152 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2020.

Based on Glenmede Trust's 13F filing for Q3 2020, filed 16 Nov 2020.